Tiziana Life Sciences (NASDAQ:TLSA) Trading Down 4.4% - Here's Why

Tiziana Life Sciences Ltd (NASDAQ:TLSA - Get Free Report)'s share price fell 4.4% on Thursday . The company traded as low as $1.70 and last traded at $1.72. 145,761 shares traded hands during mid-day trading, a decline of 42% from the average session volume of 249,876 shares. The stock had previously closed at $1.80.Get Tiziana Life Sciences alerts:Analysts Set New Price TargetsSeparately, Weiss Ratings restated a "sell (d-)" rating on shares of Tiziana Life Sciences in a report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has a consensus rating of "Sell".Check Out Our Latest Stock Analysis on TLSATiziana Life Sciences Stock Down 4.4%The business's 50 day moving average price is $1.86 and its 200-day moving average price is $1.79. Institutional Inflows and OutflowsA number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Millennium Management LLC bought a new stake in shares of Tiziana Life Sciences in the 3rd quarter valued at approximately $520,000. Jane Street Group LLC boosted its stake in Tiziana Life Sciences by 968.2% in the 1st quarter. Jane Street Group LLC now owns 167,542 shares of the company's stock valued at $181,000 after buying an additional 151,858 shares in the last quarter. OMERS ADMINISTRATION Corp acquired a new stake in Tiziana Life Sciences in the 1st quarter valued at $156,000. Bison Wealth LLC bought a new stake in Tiziana Life Sciences in the fourth quarter valued at $30,000. Finally, ARS Investment Partners LLC bought a new stake in Tiziana Life Sciences in the third quarter valued at $66,000. About Tiziana Life Sciences (Get Free Report)Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.Further ReadingFive stocks we like better than Tiziana Life SciencesESG Stocks, What Investors Should Know3 Recently Downgraded Stocks to Avoid in 2026How to Calculate Retirement Income: MarketBeat’s CalculatorThe Chip Boom Is Back: 3 Stocks Positioned for Huge GainsInsider Selling Explained: Can it Inform Your Investing Choices?Oracle Stock Hit Hard: Why Its AI Pipeline Could Drive a 2026 RallyThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Tiziana Life Sciences Right Now?Before you consider Tiziana Life Sciences, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tiziana Life Sciences wasn't on the list.While Tiziana Life Sciences currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here